Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

Ann Rheum Dis 2013 Aug 3;72(8):1308-14. Epub 2012 Sep 3.

Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK.

Background: The metabolic syndrome (MetS) may contribute to increased cardiovascular risk in systemic lupus erythematosus (SLE). We aimed to examine the association of demographic factors, lupus phenotype and therapy exposure with the presence of MetS.

Methods: The Systemic Lupus International Collaborating Clinics Registry for Atherosclerosis inception cohort enrolled recently diagnosed (<15 months) SLE patients from 30 centres across 11 countries from 2000. Clinical, laboratory and therapeutic data were collected according to a standardised protocol. MetS was defined according to the 2009 consensus statement from the International Diabetes Federation. Univariate and backward stepwise multivariate logistic regression were used to assess the relationship of individual variables with MetS.

Results: We studied 1686 patients, of whom 1494 (86.6%) had sufficient data to determine their MetS status. The mean (SD) age at enrolment and disease duration was 35.2 years (13.4) and 24.1 weeks (18.0), respectively. MetS was present at the enrolment visit in 239 (16%). In backward stepwise multivariable regression analysis, higher daily average prednisolone dose (mg) (OR 1.02, 95% CI 1.00 to 1.03), older age (years) (OR 1.04, 95% CI 1.03 to 1.06), Korean (OR 6.33, 95% CI 3.68 to 10.86) and Hispanic (OR 6.2, 95% CI 3.78 to 10.12) ethnicity, current renal disease (OR 1.79, 95% CI 1.14 to 2.80) and immunosuppressant use (OR 1.81, 95% CI 1.18 to 2.78) were associated with MetS.

Conclusions: Renal lupus, higher corticosteroid doses, Korean and Hispanic ethnicity are associated with MetS in SLE patients. Balancing disease control and minimising corticosteroid exposure should therefore be at the forefront of personalised treatment decisions in SLE patients.

Download full-text PDF

Source
http://ard.bmj.com/content/72/8/1308.full.pdf
Web Search
http://ard.bmj.com/cgi/doi/10.1136/annrheumdis-2012-202106
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2012-202106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711497PMC
August 2013
34 Reads

Publication Analysis

Top Keywords

systemic lupus
12
metabolic syndrome
8
lupus erythematosus
8
inception cohort
8
lupus phenotype
4
demographic factors
4
factors lupus
4
association demographic
4
examine association
4
cardiovascular risk
4
increased cardiovascular
4
risk systemic
4
sle aimed
4
aimed examine
4
phenotype therapy
4
presence metsmethods
4
registry atherosclerosis
4
clinics registry
4
atherosclerosis inception
4
cohort enrolled
4

References

(Supplied by CrossRef)
Lupus Atherosclerosis Prevention Study (LAPS)
Petri et al.
Ann Rheum Dis 2011
The metabolic syndrome
Cornier et al.
Endocr Rev 2008

Similar Publications